Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14834704 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2L3MBTL1ALDH1A1HTTKMT2A | |
| SCHEMBL7143543 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2L3MBTL1ALDH1A1HTTKMT2A | |
| SCHEMBL4703205 | 0.95 | SMN1; SMN2 (0.37) | SMN1; SMN2L3MBTL1ALDH1A1HTTKMT2A | |
| SCHEMBL14834486 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AGAA | |
| SCHEMBL14834460 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AGAA | |
| SCHEMBL3966132 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AGAA | |
| SCHEMBL14834692 | 0.86 | LMNA (0.35) | SMN1; SMN2L3MBTL1DRD2 | |
| SCHEMBL14834396 | 0.86 | LMNA (0.35) | SMN1; SMN2L3MBTL1DRD2 | |
| SCHEMBL11972105 | 0.80 | OPRM1 (0.36) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL15049918 | 0.80 | OPRM1 (0.36) | SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771340-B1 | 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-04-13 | — | — | EP | claimed |
| EP-2576537-B1 | 2-AMINO-PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2016-03-16 | — | — | EP | claimed |
| US-8642601-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2014-02-04 | — | — | US | claimed |
| US-20130150340-A1 | 6-(4-Hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | SANOFI (FR) | 2013-06-13 | — | — | US | claimed |
| EP-2576537-A1 | 2 -AMINO- PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-10 | — | — | EP | claimed |
| WO-2011151358-A1 | 2 -AMINO- PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | claimed |
| US-20110301171-A1 | Inhibitors of JNK | ARZENO HUMBERTO BARTOLOME (US) | 2011-12-08 | — | — | US | claimed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | claimed |
| US-20100240645-A1 | COMBINATION OF CHECKPONIT KINASE (CHK) AND TELANGIECTASIA MUTATED (ATM) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-09-23 | — | — | US | claimed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | claimed |
| JP-2007513193-A | — | — | 2007-05-24 | — | — | JP | claimed |
| EP-1761519-A1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| EP-1732920-A2 | THIOPHENE DERIVATIVES AS CHK 1 INHIBITORS | AstraZeneca AB (SE) | 2006-12-20 | — | — | EP | claimed |
| EP-1694673-A1 | NOVEL THIAZOLE DERIVATES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-30 | — | — | EP | claimed |
| WO-2005123716-A1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | claimed |
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. | 2005-12-22 | — | — | US | claimed |
| WO-2005066163-A2 | THIOPHENE DERIVATIVES AS CHK 1 INIHIBITORS | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | claimed |
| US-20050153962-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | claimed |
| WO-2005058887-A1 | NOVEL THIAZOLE DERIVATES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150340-A1 | 6-(4-Hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | MAP3K1, MAP4K2, MAP3K19 | SMN1; SMN2 2861/4885L3MBTL1 4102/4885ALDH1A1 934/4885 |
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | CHEK1, CHKA, CHEK2 | SMN1; SMN2 4643/4885L3MBTL1 2105/4885ALDH1A1 2326/4885 |
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HRH3, HRH4, ADRB1 | SMN1; SMN2 3987/4885L3MBTL1 2719/4885ALDH1A1 2007/4885 |
| US-20100240645-A1 | COMBINATION OF CHECKPONIT KINASE (CHK) AND TELANGIECTASIA MUTATED (ATM) INHIBITORS FOR THE TREATMENT OF CANCER | CHEK2, ATM, CHEK1 | SMN1; SMN2 1432/4885L3MBTL1 1713/4885ALDH1A1 4410/4885 |
| US-20110301171-A1 | Inhibitors of JNK | MAPK9, MAP3K9, MAPK1 | SMN1; SMN2 3209/4885L3MBTL1 1546/4885ALDH1A1 4409/4885 |
| US-20050153962-A1 | Thiazole derivatives | CNR1, CNR2, GPR119 | SMN1; SMN2 3460/4885L3MBTL1 2979/4885ALDH1A1 473/4885 |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | CHEK1, CHEK2, PARP1 | SMN1; SMN2 2368/4885L3MBTL1 1519/4885ALDH1A1 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.